New legal opinion: New GMOs deregulation proposal shifts safety testing, liability to EU food industry
By GMWatch Staff,
GMWatch
| 01. 14. 2025
Photo by Markus Winkler on Unsplash
The planned deregulation of new GMOs (new genomic techniques, NGTs) in the EU would shift safety testing and liability risks for plants produced with NGTs and the products derived from them, from biotech companies to the food industry. These consequences, until now unnoticed, of the EU Commission's plans to deregulate new GMOs are highlighted in a new legal opinion by the Berlin law firm GGSC on behalf of ENGA’s member VLOG (German Association for Food without Genetic Engineering). ENGA is the voice of the Non-GMO food and feed sector at the EU level.
EU Commission’s plans to deregulate new GMOs are to the detriment of the EU food sector
Heike Moldenhauer, Secretary General of ENGA, said: “With its plans to deregulate New GMOs, the European Commission is throwing the EU’s food sector ‘to the wolves’, by shifting the costs and risks from biotech to the food sector. This is unacceptable and may become a major problem for the entire EU food industry, not just the organic and ‘Non-GMO’ sectors.”
Biotechnology companies must take responsibility...
Related Articles
By Lucy Tu, The Atlantic | 07.11.2025
Donald Trump—who is, by his own accounting, “the fertilization president” and “the father of IVF”—wants to help Americans reproduce. During his 2024 campaign, he promised that the government or insurance companies would cover the cost of in vitro fertilization. In...
By Jared Whitlock, Endpoints News | 07.15.2025
Patient groups face a harder and unpredictable path going state-by-state to boost screening for rare but treatable conditions after the Trump administration disbanded a federal advisory committee on newborn screening.
In April, the Advisory Committee on Heritable Disorders in Newborns...
By Ben Fidler and Ned Pagliarulo, Biopharma Dive | 07.21.2025
One month ago, a 51-year-old man treated in a clinical trial with an experimental gene therapy became dangerously sick. The developer of that treatment, Sarepta Therapeutics, informed the Food and Drug Administration his case could be life-threatening.
The man died...
By Pat Duggins, Alabama Public Radio | 06.27.2025
PAT DUGGINS-- If I were to say, ‘man, have you seen the price of eggs these days?’ You're probably thinking, Oh, he's talking about inflation and the price of groceries and how it became an issue in the presidential race...